Sanofi Adds mRNA Specialist Tidal To Acquisition Spree
Focus Again On Cancer and Immunology
Sanofi has paid out $160m to add to its in-house expertise in mRNA and novel cell therapy technologies.
You may also be interested in...
Taking full control of partner Translate Bio means that Sanofi is the only big vaccine company with a wholly-owned mRNA platform in-house but observers say it is too early to declare that the Paris-headquartered group has bagged itself a bargain.
The UK drug discovery specialist has made slow progress until now, but the Sanofi deal could yield a challenger in the competitive psoriasis field.
Argenx partners with Elektrofi and Iontas; China’s Qilu obtains global rights to Peptron’s antibody-drug conjugate and also ends co-development pact with Quantum Genomics.